BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Rapid Blood Test Identifies Deadly Brain Cancer in Just One Hour

NextEdge Admin

02 Sep 2024

1 min 46 sec

Scientists have developed a novel, less invasive method to detect brain cancer, particularly glioblastoma, using just 100 microliters of blood. This liquid biopsy, created by a team led by the University of Notre Dame, can detect cancer biomarkers within an hour, offering a faster alternative to traditional surgical biopsies.

The test targets epidermal growth factor receptors (EGFRs), which are overexpressed in certain cancers like glioblastoma. These biomarkers are found inside extracellular vesicles, nanoparticles secreted by cancer cells. Researchers use a biochip, costing under $2, equipped with a tiny sensor that detects the presence of mutated EGFRs through a voltage change in the plasma solution.

In tests on clinical blood samples from glioblastoma patients and healthy individuals, the biochip demonstrated excellent accuracy, detecting even low concentrations of exosomes. However, because EGFR mutations are also associated with other cancers, the test cannot diagnose all glioblastoma cases or specify cancer type and stage. The team plans to refine the test by analyzing larger patient cohorts to identify more specific biomarkers. This breakthrough has significant potential for broader cancer research and diagnosis.